Key Takeaways Cardinal Health is emerging as a stronger bet, driven by a turnaround and accelerating growth momentum.CAH posted 19% revenue growth and 38% earnings growth in fiscal Q2, fueled by pharma demand.McKesson delivers steady gains, but its growth remains incremental versus Cardinal Health's upside.Cardinal Health (CAH) and McKesson (MCK) are two of the largest pharmaceutical distributors globally, playing a critical role in the healthcare supply chain. Cardinal Health has recently re-emerged with s ...

Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Strategy lagged the Russell Midcap® Growth Index in the fourth quarter due to stock selection. The performance was in line with expectations for the full year. The firm believes that the Strategy underperformed in 2025 because it did not own Palantir Technologies Inc (PLTR). The Strategy focuses on achieving solid risk-a ...

Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2026 on April 30 Accessibility StatementSkip NavigationDUBLIN, Ohio, March 24, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2026 on April 30 as previously indicated, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern.To access the webcast and corresponding slide presentatio ...

Key Takeaways Cardinal Health saw GLP-1 drugs add about six percentage points to segment revenue growth in Q2 FY26.CAH benefits from strong demand in injectable GLP-1s, driving higher distribution volumes across pharma.Oral GLP-1 adoption may grow over time, supporting sustained top-line gains despite modest profit impact.Cardinal Health (CAH) is clearly benefiting from the rapid adoption of GLP-1 therapies, though the impact remains more pronounced on revenues than profitability. In the second quarter of f ...

Cardinal Health Appoints Patricia A. Hemingway Hall as Board Chair Accessibility StatementSkip NavigationDUBLIN, Ohio, March 23, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced that its Board of Directors has appointed Patricia A. Hemingway Hall to succeed Gregory B. Kenny as Chair of the Board following Mr. Kenny's retirement, effective immediately.Mr. Kenny has served on the Board since 2007 and as Chairman since 2018. During his tenure on the Board, Mr. Kenny supported the Company throug ...

Core Insights - Cardinal Health (CAH) is experiencing strong cash generation in fiscal 2026, with approximately $1.8 billion in adjusted free cash flow, enhancing its capital allocation flexibility [1][10] Financial Performance - CAH has returned about $1 billion to shareholders, comprising $750 million in share repurchases and $250 million in dividends, reflecting management's commitment to delivering near-term value [2][10] - The company allocated around $240 million to capital expenditures to support organic growth initiatives [2] Balance Sheet and Leverage - CAH's leverage ratio has improved to 3.2x, within the targeted range of 2.75x to 3.25x, enhancing financial flexibility and allowing for potential capital deployment opportunities [3][5] Capital Allocation Strategy - The company is adopting a disciplined and opportunistic approach to capital deployment, balancing reinvestment in high-growth areas with returns to shareholders [4][5] - While large-scale M&A is not a strategic necessity, CAH remains open to targeted acquisitions in fragmented markets like at-Home Solutions and specialty services [5] Market Position and Valuation - CAH's shares have surged 42.4% over the past six months, outperforming the industry growth of 14.4% [13] - The company trades at a forward price-to-earnings ratio of 19.09, above the industry average and its five-year median of 13.47 [14] - The Zacks Consensus Estimate for CAH's fiscal 2026 earnings indicates a 25.1% increase from the previous year [15]

Core Viewpoint - Cardinal Health's stock has shown a decline recently, but upcoming earnings are expected to reflect significant growth in both earnings per share and revenue compared to the previous year [1][2]. Group 1: Stock Performance - Cardinal Health closed at $211.87, down 2.08% from the previous day, which is less than the S&P 500's loss of 1.36% [1] - Over the past month, Cardinal Health's shares have depreciated by 4.09%, outperforming the Medical sector's loss of 5.66% but lagging behind the S&P 500's loss of 1.76% [1] Group 2: Earnings Projections - The upcoming earnings release is projected to show earnings per share (EPS) of $2.8, a 19.15% increase from the same quarter last year [2] - Revenue is expected to reach $62.42 billion, indicating a 13.74% increase compared to the same quarter of the previous year [2] - For the full year, analysts expect earnings of $10.31 per share and revenue of $259.27 billion, reflecting changes of +25.12% and +16.48% respectively from last year [3] Group 3: Analyst Estimates and Rankings - Recent changes to analyst estimates for Cardinal Health indicate positive sentiment regarding the company's business operations and profit generation capabilities [4] - The Zacks Rank system currently rates Cardinal Health as 2 (Buy), with a consensus EPS projection having moved 0.04% higher in the past 30 days [6] Group 4: Valuation Metrics - Cardinal Health is trading at a Forward P/E ratio of 20.98, which is higher than the industry average of 15.71, suggesting a premium valuation [7] - The company's PEG ratio is currently 1.39, compared to the Medical - Dental Supplies industry's average PEG ratio of 1.82, indicating a favorable growth outlook [8] Group 5: Industry Context - The Medical - Dental Supplies industry, part of the Medical sector, has a Zacks Industry Rank of 62, placing it in the top 26% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1, highlighting the potential for investment opportunities within this sector [9]

Core Viewpoint - Cardinal Health stock is currently in a buy zone, maintaining stability amid macroeconomic challenges such as the U.S.-Israeli war and drug pricing negotiations [1] Financial Performance - In the fiscal second quarter, Cardinal Health reported a 19% increase in pharmaceutical and specialty solutions sales, totaling $60.7 billion [1] - The global medical products and distribution unit generated $3.3 billion in sales, reflecting a 3% increase [1] - The "other" segment, which includes at-home solutions and nuclear/precision health solutions, saw a significant 34% year-over-year growth, generating $1.7 billion [1] Market Position and Analyst Sentiment - Cardinal Health is recognized as one of the top three medical wholesalers in the U.S., alongside McKesson and Cencora [1] - Analysts have given positive reviews, noting strong demand and effective execution across all business segments, with double-digit profit growth reported [1] - The company is expanding into specialty drugs and has made acquisitions to enhance its capabilities in this area [1] Stock Performance and Technical Indicators - Cardinal Health stock has a strong IBD Digital Relative Strength Rating of 91 out of 99, indicating robust performance compared to other stocks [1] - The stock has a Composite Rating of 94, placing it in the top 6% of all stocks across industries [1] - The stock remains above its 50-day and 200-day moving averages, indicating a favorable technical position [1]

Core Insights - Cardinal Health (CAH) demonstrated strong performance in fiscal Q2 2026, with revenues from its Pharmaceutical and Specialty Solutions segment increasing by 19% year over year to $61 billion, and profits rising by 29% to $687 million, solidifying its role as the main earnings driver for the company [1][9]. Growth Drivers - The growth was primarily driven by robust pharmaceutical demand, momentum in specialty drugs, and enhanced operational efficiency within the distribution network. Notably, GLP-1 medications contributed approximately 6 percentage points to revenue growth during the quarter, indicating strong demand for these therapies [2][3]. - Cardinal Health's focus on specialty pharmaceuticals is a significant catalyst for growth, with expectations that specialty revenues will surpass $50 billion in fiscal 2026, highlighting the segment's increasing importance [3][4]. - The Red Oak generics program has also been a key contributor, with healthy generic unit growth exceeding long-term expectations, providing a stable source of margin expansion [5]. - New customer onboarding and strong demand from existing clients have bolstered the pharmaceutical distribution platform, while technology investments have improved operational efficiency, supporting margins and enhancing customer experience [6][7]. Financial Outlook - Estimates for Cardinal Health's fiscal 2026 earnings have increased by 25.1% to $10.31 per share over the past year, with fiscal 2027 earnings improving by 10.6% to $11.40, reflecting positive sentiment towards the stock [8]. - The company raised its fiscal 2026 EPS outlook to a range of $10.15-$10.35, indicating a year-over-year growth of approximately 23-26% [13][21]. Competitive Landscape - Cardinal Health operates in a concentrated pharmaceutical distribution industry alongside competitors like McKesson (MCK) and Cencora (COR). Despite intense competition, Cardinal Health maintains a strong position due to its scale, supply-chain expertise, and diversified services [10][12]. - McKesson has reported strong results driven by growth in oncology services and biopharma solutions, while Cencora is expanding its specialty platform through acquisitions [10][11]. Price Performance - Cardinal Health's shares have surged by 73.5% over the past year, outperforming the industry growth of 15.9% and the S&P 500 Index's increase of 26%. The company has also outperformed peers McKesson and Cencora, which gained 45.3% and 37.7%, respectively [14]. - The shares currently trade at a forward 12-month price-to-earnings (P/E) ratio of 19.45X, higher than the industry average of 18.01X, indicating strong earnings visibility and guidance [18]. Conclusion - The Pharmaceutical and Specialty Solutions segment remains the primary growth engine for Cardinal Health, with strong specialty drug demand, a robust generics program, and improved operational efficiency supporting earnings momentum. The strategic focus on specialty distribution and physician services presents a durable long-term opportunity for the company [21][22][24].

Core Insights - Cardinal Health's accelerating specialty strategy is central to its earnings expansion, with adjusted EPS guidance for fiscal 2026 raised to $10.15-$10.35, indicating a 23-26% year-over-year growth [1][10] Financial Performance - The Pharmaceutical and Specialty Solutions segment is driving momentum, benefiting from strong demand for brand and specialty drugs, leading to significant profit growth supported by a favorable product mix and cost management [2] - Cardinal Health expects specialty revenues to exceed $50 billion in fiscal 2026, indicating substantial growth in this higher-margin segment [3][10] - The company has raised its fiscal 2026 adjusted EPS guidance, reflecting strong operational execution and continued demand across its pharmaceutical platform [1][10] Strategic Initiatives - A key component of the growth strategy is the rapid expansion of Cardinal Health's specialty ecosystem, including partnerships with physician practices through MSO platforms [4][6] - The acquisition of Solaris Health enhances Cardinal Health's capabilities in the urology specialty, further expanding its footprint [4] - The biopharma services business, including the Sonexus patient-support platform, is gaining traction, reinforcing Cardinal Health's role in the specialty value chain [5][6] Industry Context - Competitors McKesson and Cencora are also expanding into specialty pharmaceuticals, with McKesson reporting double-digit revenue and EPS growth driven by oncology services [7][8] - Cencora reported 12% operating income growth and 9% EPS growth, largely due to its U.S. Healthcare Solutions segment and specialty drug demand [9] Valuation and Estimates - Cardinal Health's shares have gained 5.2% over the past six months, outperforming the industry average of 1.4% [12] - The company trades at a forward price-to-earnings ratio of 19.45, above the industry average and its five-year median of 13.46 [13] - The Zacks Consensus Estimate for fiscal 2026 earnings implies a 25.1% rise from the previous year [14]